Sangamo Therapeutics Inc (NASDAQ:SGMO) currently has a daily average trading volume of 7.33M but it saw 15326462 shares traded in last market. With a market cap of 585.11M USD, the company’s current market price of $2.81 came rising about 13.77 while comparing to the previous closing price of $2.47. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.56 and as low as $0.29. In the recent trading on the day, stock has struck highest price mark of $2.44 while lowest mark touched by it was $2.97.
Taking a look at 20-day trading activity of Sangamo Therapeutics Inc (SGMO) gives us an average price of $1.55, while its current price level is 9.98% below from 52-week high level whereas it is 865.30% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.12 while that of 200 days or SMA-200 reads an average of $0.77. A closer look into the stock’s movement over the week reveals that its volatility is standing at 20.55% during that period while stretching the period over a month that decreases to 18.84%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 80.25 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the RBC Capital Mkts which downgraded the stock as “Sector Perform” in its note to investors issued on November 03, 2023, recommending a price target of between $6 and $2 for it. BofA Securities downgraded its recommendation for the stock as a “Underperform” from “Neutral” on April 28, 2023 while assigning a price target range of $5-$1.50. Wedbush issued its recommendations for the stock as it upgraded the price target for the stock is $16.
Over the week, SGMO’s stock price is moving 65.29% up while it is 255.70% when we observe its performance for the past one month. Year-to-date it is 417.21% up and over the past year, the stock is showing an upside performance of 569.05%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.59 beaten by the consensus estimate of -0.32 for the same. The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.03 while estimate for next year EPS is -0.48. In next quarter, company is expected to be making quarterly sales of $8.17M as analysts are expecting the sales for current fiscal year at $48.05M and seeing the company making $82.55M in sales next year. Moreover, analysts are in estimates of $17.94M for current-quarter revenue.
Currently, Sangamo Therapeutics Inc’s total number of outstanding shares is 208.22M. Company’s return on investment (ROI) stands at -472.99% and return on equity (ROE) at -194.05%. Stock’s beta reads 1.15. Stock has a price to book (P/B) ratio of 24.70 while price to sale or P/S ratio amounts to 47.65. Its return on asset (ROA) is -119.44% on average.
